{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:19:25Z","timestamp":1778861965989,"version":"3.51.4"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02312-2","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:57:13Z","timestamp":1775901433000},"page":"841-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-607X","authenticated-orcid":false,"given":"Nicholas A.","family":"Tritos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"19","key":"2312_CR1","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A. Acromegaly. N Engl J Med. 2025;393(19):1926\u201339.","journal-title":"N Engl J Med"},{"issue":"10","key":"2312_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020;382(10):937\u201350.","journal-title":"N Engl J Med"},{"issue":"16","key":"2312_CR3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/jama.2023.5444","volume":"329","author":"NA Tritos","year":"2023","unstructured":"Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023;329(16):1386\u201398.","journal-title":"JAMA"},{"issue":"1","key":"2312_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","volume":"179","author":"F Bolfi","year":"2018","unstructured":"Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179(1):59\u201371.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2312_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/EJE-19-0794","volume":"182","author":"NA Tritos","year":"2020","unstructured":"Tritos NA, Mattsson AF, Vila G, Biller BMK, Klibanski A, Valluri S, et al. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Eur J Endocrinol. 2020;182(3):285\u201392.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2312_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1530\/ERC-16-0106","volume":"23","author":"E Ritvonen","year":"2016","unstructured":"Ritvonen E, Loyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, et al. Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer. 2016;23(6):469\u201380.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2312_CR7","first-page":"3419","volume":"83","author":"B Swearingen","year":"1998","unstructured":"Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83(10):3419\u201326.","journal-title":"J Clin Endocrinol Metab"},{"key":"2312_CR8","doi-asserted-by":"publisher","unstructured":"Tritos NA, Carlsson MO, Vila G, Jimenez C, La Torre D, Wajnrajch MP, et al. Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Endocr Connect. 2025;14(9):e250247. https:\/\/doi.org\/10.1530\/EC-25-0247.","DOI":"10.1530\/EC-25-0247"},{"issue":"4","key":"2312_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1210\/jc.2011-3237","volume":"97","author":"B Swearingen","year":"2012","unstructured":"Swearingen B. Update on pituitary surgery. J Clin Endocrinol Metab. 2012;97(4):1073\u201381.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2312_CR10","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr., Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2312_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M, Mercado M, Karavitaki N, Gurnell M, et al. Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol. 2025;21(11):718\u201337.","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"2312_CR12","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00701-016-2903-4","volume":"158","author":"D Starnoni","year":"2016","unstructured":"Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien). 2016;158(11):2109\u201321.","journal-title":"Acta Neurochir (Wien)"},{"issue":"10","key":"2312_CR13","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00701-023-05772-7","volume":"165","author":"CM Falch","year":"2023","unstructured":"Falch CM, Dupont AK, Olarescu NC, Wiedmann M, Dahlberg D, Bollerslev J, et al. Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Acta Neurochir (Wien). 2023;165(10):3003\u201310.","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"2312_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11102-014-0602-9","volume":"18","author":"VS Nunes","year":"2015","unstructured":"Nunes VS, Correa JM, Puga ME, Silva EM, Boguszewski CL. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary. 2015;18(4):500\u20138.","journal-title":"Pituitary"},{"issue":"2","key":"2312_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.mayocp.2021.11.007","volume":"97","author":"N Ershadinia","year":"2022","unstructured":"Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: an update. Mayo Clin Proc. 2022;97(2):333\u201346.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2312_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11154-007-9065-x","volume":"9","author":"HA Shih","year":"2008","unstructured":"Shih HA, Loeffler JS. Radiation therapy in acromegaly. Rev Endocr Metab Disord. 2008;9(1):59\u201365.","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"2312_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3171\/2021.2.JNS204440","volume":"136","author":"D Mathieu","year":"2022","unstructured":"Mathieu D, Kotecha R, Sahgal A, De Salles A, Fariselli L, Pollock BE, et al. Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations. J Neurosurg. 2022;136(3):801\u201312.","journal-title":"J Neurosurg"},{"issue":"4","key":"2312_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pr.117.015388","volume":"70","author":"T Gunther","year":"2018","unstructured":"Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev. 2018;70(4):763\u2013835.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"2312_CR19","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2312_CR20","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282\u201390.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2312_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1\u201313.","journal-title":"Pituitary"},{"issue":"5","key":"2312_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE. 2012;7(5):e36411. https:\/\/doi.org\/10.1371\/journal.pone.0036411.","journal-title":"PLoS ONE"},{"issue":"8","key":"2312_CR23","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","volume":"31","author":"S Tuvia","year":"2014","unstructured":"Tuvia S, Pelled D, Marom K, Salama P, Levin-Arama M, Karmeli I, et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res. 2014;31(8):2010\u201321.","journal-title":"Pharm Res"},{"issue":"4","key":"2312_CR24","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","volume":"100","author":"S Melmed","year":"2015","unstructured":"Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015;100(4):1699\u2013708.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2312_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, et al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2022;10(2):102\u201311.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2312_CR26","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/bcp.12698","volume":"80","author":"F Tiberg","year":"2015","unstructured":"Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Tripathi AP, et al. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Br J Clin Pharmacol. 2015;80(3):460\u201372.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2312_CR27","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","volume":"110","author":"D Ferone","year":"2025","unstructured":"Ferone D, Freda P, Katznelson L, Gatto F, Kadioglu P, Maffei P, et al. Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. J Clin Endocrinol Metab. 2025;110(6):1729\u201339.","journal-title":"J Clin Endocrinol Metab"},{"key":"2312_CR28","doi-asserted-by":"crossref","unstructured":"Ferone D, Silverstein JM, Freda P, Katznelson L, Gatto F, Kadioglu P, et al. CAM2029, octreotide subcutaneous depot, provides sustained biochemical control of acromegaly: interim results from a phase 3 study (ACROINNOVA 2). J Endocr Soc. 2024;8 (Suppl 1):bvae163.1155.","DOI":"10.1210\/jendso\/bvae163.1155"},{"issue":"5","key":"2312_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707\u201316.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2312_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2312_CR31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2312_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.935759","volume":"13","author":"A Mondin","year":"2022","unstructured":"Mondin A, Manara R, Voltan G, Tizianel I, Denaro L, Ferrari M, et al. Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:935759.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2312_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","volume":"14","author":"J Zhao","year":"2023","unstructured":"Zhao J, Wang S, Markison S, Kim SH, Han S, Chen M, et al. Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist. ACS Med Chem Lett. 2023;14(1):66\u201374.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2312_CR34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41467-023-36673-z","volume":"14","author":"J Zhao","year":"2023","unstructured":"Zhao J, Fu H, Yu J, Hong W, Tian X, Qi J, et al. Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine. Nat Commun. 2023;14(1):962.","journal-title":"Nat Commun"},{"issue":"1","key":"2312_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1210\/clinem\/dgae385","volume":"110","author":"MR Gadelha","year":"2024","unstructured":"Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, et al. Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. J Clin Endocrinol Metab. 2024;110(1):228\u201337.","journal-title":"J Clin Endocrinol Metab"},{"key":"2312_CR36","doi-asserted-by":"publisher","unstructured":"Biller BMK, Casagrande A, Elenkova A, Boguszewski CL, Jallad RS, Hu B, et al. Rapid and sustained response of biochemically uncontrolled acromegaly to once-daily oral paltusotine treatment. J Clin Endocrinol Metab. 2026;111(4):e1050\u2013e1063. https:\/\/doi.org\/10.1210\/clinem\/dgaf579.","DOI":"10.1210\/clinem\/dgaf579"},{"issue":"9","key":"2312_CR37","doi-asserted-by":"publisher","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","volume":"107","author":"L Maione","year":"2022","unstructured":"Maione L, Albrici C, Grunenwald S, Mouly C, Cimino V, Lecoq AL, et al. IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands. J Clin Endocrinol Metab. 2022;107(9):e3644\u201353.","journal-title":"J Clin Endocrinol Metab"},{"key":"2312_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1250822","volume":"15","author":"U Feldt-Rasmussen","year":"2024","unstructured":"Feldt-Rasmussen U, Bolanowski M, Zhang SL, Yu Y, Witek P, Kalra P, et al. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing\u2019s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study. Front Endocrinol (Lausanne). 2024;15:1250822.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2312_CR39","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446\u201353.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2312_CR40","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary. 2021;24(6):887\u2013903.","journal-title":"Pituitary"},{"issue":"12","key":"2312_CR41","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722\u201340.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2312_CR42","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1210\/jc.2010-2443","volume":"96","author":"L Sandret","year":"2011","unstructured":"Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2312_CR43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):863\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2312_CR44","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.eprac.2025.04.018","volume":"31","author":"G Daftari","year":"2025","unstructured":"Daftari G, Tritos NA. Impulse control disorders in patients with hyperprolactinemia on dopamine agonist therapy-How concerned should we be? Endocr Pract. 2025;31(7):938\u201345.","journal-title":"Endocr Pract"},{"key":"2312_CR45","doi-asserted-by":"publisher","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J, et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab. 2020;105(3):dgz076. https:\/\/doi.org\/10.1210\/clinem\/dgz076.","DOI":"10.1210\/clinem\/dgz076"},{"issue":"7","key":"2312_CR46","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z, et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab. 2019;104(7):2527\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2312_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med. 2007;356(1):39\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"2312_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29\u201338.","journal-title":"N Engl J Med"},{"issue":"2","key":"2312_CR49","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1210\/clinem\/dgaa882","volume":"106","author":"CE Stiles","year":"2021","unstructured":"Stiles CE, Lloyd G, Bhattacharyya S, Steeds RP, Boomla K, Bestwick JP, et al. Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J Clin Endocrinol Metab. 2021;106(2):e711\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2312_CR50","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/cen.13940","volume":"90","author":"R Steeds","year":"2019","unstructured":"Steeds R, Stiles C, Sharma V, Chambers J, Lloyd G, Drake W. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf). 2019;90(5):662\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 2","key":"2312_CR51","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1530\/eje.0.148s021","volume":"148","author":"JJ Kopchick","year":"2003","unstructured":"Kopchick JJ. Discovery and mechanism of action of pegvisomant. Eur J Endocrinol. 2003;148(Suppl 2):S21\u20135.","journal-title":"Eur J Endocrinol"},{"issue":"16","key":"2312_CR52","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171\u20137.","journal-title":"N Engl J Med"},{"issue":"9295","key":"2312_CR53","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","volume":"358","author":"AJ van der Lely","year":"2001","unstructured":"van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754\u20139.","journal-title":"Lancet"},{"issue":"4","key":"2312_CR54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Fuhrer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol. 2021;185(4):525\u201338.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2312_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4158\/EP14330.OR","volume":"21","author":"PU Freda","year":"2015","unstructured":"Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract. 2015;21(3):264\u201374.","journal-title":"Endocr Pract"},{"issue":"12","key":"2312_CR56","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1210\/jc.2007-1234","volume":"92","author":"SJ Neggers","year":"2007","unstructured":"Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007;92(12):4598\u2013601.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2312_CR57","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4158\/EP-2019-0528","volume":"26","author":"N Qiao","year":"2020","unstructured":"Qiao N, He M, Shen M, Zhang Q, Zhang Z, Shou X, et al. Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies. Endocr Pract. 2020;26(4):454\u201362.","journal-title":"Endocr Pract"},{"issue":"4","key":"2312_CR58","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5603\/EP.a2019.0023","volume":"70","author":"A Colao","year":"2019","unstructured":"Colao A, Zgliczynski W, Komorowski J, Kos-Kudla B, Tabarin A, Kerlan V, et al. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Endokrynol Pol. 2019;70(4):305\u201312.","journal-title":"Endokrynol Pol"},{"issue":"10","key":"2312_CR59","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.1210\/jc.2005-0331","volume":"90","author":"AL Barkan","year":"2005","unstructured":"Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2312_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-16-0697","volume":"176","author":"NA Tritos","year":"2017","unstructured":"Tritos NA, Chanson P, Jimenez C, King D, Jonsson PJ, Klibanski A, et al. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. Eur J Endocrinol. 2017;176(2):213\u201320.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2312_CR61","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T, Cozzolino A, Simonelli I, Sbardella E, Pozza C, Giannetta E, et al. Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 2019;104(7):2892\u2013902.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2312_CR62","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/EJE-18-0616","volume":"179","author":"M Buchfelder","year":"2018","unstructured":"Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol. 2018;179(6):419\u201327.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2312_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11102-016-0753-y","volume":"20","author":"NA Tritos","year":"2017","unstructured":"Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary. 2017;20(1):129\u201335.","journal-title":"Pituitary"},{"issue":"2","key":"2312_CR64","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","volume":"23","author":"S Petersenn","year":"2020","unstructured":"Petersenn S, Houchard A, Sert C, Caron PJ, Group PS. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary. 2020;23(2):171\u201381.","journal-title":"Pituitary"},{"key":"2312_CR65","doi-asserted-by":"publisher","unstructured":"Asa SL, Ezzat S. An update on pituitary neuroendocrine tumors leading to acromegaly and gigantism. J Clin Med. 2021;10(11):2254. https:\/\/doi.org\/10.3390\/jcm10112254.","DOI":"10.3390\/jcm10112254"},{"issue":"2","key":"2312_CR66","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","volume":"52","author":"A Heck","year":"2016","unstructured":"Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. 2016;52(2):333\u201343.","journal-title":"Endocrine"},{"issue":"1","key":"2312_CR67","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","volume":"77","author":"A Heck","year":"2012","unstructured":"Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2012;77(1):72\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2312_CR68","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1210\/jc.2010-0573","volume":"95","author":"M Puig-Domingo","year":"2010","unstructured":"Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010;95(11):4973\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2312_CR69","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11102-019-01023-0","volume":"23","author":"BP Galm","year":"2020","unstructured":"Galm BP, Buckless C, Swearingen B, Torriani M, Klibanski A, Bredella MA, et al. MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands. Pituitary. 2020;23(3):212\u201322.","journal-title":"Pituitary"},{"issue":"11","key":"2312_CR70","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","volume":"107","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grange L, Schillo F, et al. Predictive factors of somatostatin receptor ligand response in acromegaly\u2014a prospective study. J Clin Endocrinol Metab. 2022;107(11):2982\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2312_CR71","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1210\/jc.2018-01360","volume":"104","author":"C Scaroni","year":"2019","unstructured":"Scaroni C, Albiger N, Daniele A, Dassie F, Romualdi C, Vazza G, et al. Paradoxical GH increase during OGTT is associated with first-generation somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2019;104(3):856\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2312_CR72","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s00330-018-5876-2","volume":"29","author":"B Kocak","year":"2019","unstructured":"Kocak B, Durmaz ES, Kadioglu P, Polat Korkmaz O, Comunoglu N, Tanriover N, et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019;29(6):2731\u20139.","journal-title":"Eur Radiol"},{"issue":"1","key":"2312_CR73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1210\/clinem\/dgae444","volume":"110","author":"M Marques-Pamies","year":"2024","unstructured":"Marques-Pamies M, Gil J, Sampedro-Nunez M, Valassi E, Biagetti B, Gimenez-Palop O, et al. Personalized medicine in acromegaly: the ACROFAST study. J Clin Endocrinol Metab. 2024;110(1):30\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2312_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.02.001","volume":"33","author":"L Maione","year":"2019","unstructured":"Maione L, Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101264.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2312_CR75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","volume":"20","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S, et al. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord. 2020;20(1):117.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"2312_CR76","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ejendo\/lvaf200","volume":"193","author":"I Remba-Shapiro","year":"2025","unstructured":"Remba-Shapiro I, Schweizer J, Moscona-Nissan A, Liebert KJP, Jones PS, Schilbach K, et al. Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection. Eur J Endocrinol. 2025;193(4):564\u201373.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2312_CR77","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","volume":"23","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, et al. Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary. 2020;23(2):140\u20138.","journal-title":"Pituitary"},{"issue":"12","key":"2312_CR78","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1080\/17512433.2021.1986004","volume":"14","author":"S Neggers","year":"2021","unstructured":"Neggers S, Badiu C, Biagetti B, Durand-Gasselin L, Petit A, Petrossians P, et al. Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly. Expert Rev Clin Pharmacol. 2021;14(12):1551\u201360.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2312_CR79","unstructured":"Bellon A, Klein J, Spaggiari D, Marquardt M, Frerart F, Rechavi-Robinson D, et al. Debio 4126, a new 3-month octreotide formulation, provides sustained release of octreotide, as well as enhanced bioavailability and similar suppression of insulin-like growth factor 1 (IGF-1), compared to monthly Sandostatin LAR in healthy volunteers\u2014interim results. In: Study presented at: 20th Congress of the European NeuroEndocrine Association, Lyon, France, Bioscientifica. 2022."},{"key":"2312_CR80","unstructured":"Ispas-Jouron S, Menetrey A, Rechavi-Robinson D, Biasse D, Marquardt M, Gavillet B, et al. Debio 4126, a new 12-week octreotide formulation, provides maintenance of disease control in patients with acromegaly swtiching from long-acting somatostatin analogues (SSAS)\u2014preliminary results. In: Study presented at: 21th congress of the European NeuroEndocrine Association, Sevilla, Spain, Bioscientifica. 2024."},{"issue":"3","key":"2312_CR81","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s12020-024-03741-3","volume":"84","author":"M Johnsson","year":"2024","unstructured":"Johnsson M, Pedroncelli AM, Hansson A, Tiberg F. Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide. Endocrine. 2024;84(3):1125\u201334.","journal-title":"Endocrine"},{"issue":"8","key":"2312_CR82","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/BF03347512","volume":"27","author":"I Shimon","year":"2004","unstructured":"Shimon I, Rubinek T, Hadani M, Alhadef N. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J Endocrinol Invest. 2004;27(8):721\u20137.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2312_CR83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1530\/EJE-11-0737","volume":"166","author":"U Plockinger","year":"2012","unstructured":"Plockinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in octreotide non-responsive tumours. Eur J Endocrinol. 2012;166(2):223\u201334.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2312_CR84","doi-asserted-by":"publisher","first-page":"K8","DOI":"10.1093\/ejendo\/lvad171","volume":"190","author":"D Regazzo","year":"2024","unstructured":"Regazzo D, Avallone S, MacSweeney CP, Sergeev E, Howe D, Godwood A, et al. A novel somatostatin receptor ligand for human ACTH- and GH-secreting pituitary adenomas. Eur J Endocrinol. 2024;190(1):K8\u201316.","journal-title":"Eur J Endocrinol"},{"key":"2312_CR85","doi-asserted-by":"publisher","unstructured":"Hata T, Uematsu Y, Sugita A, Adachi H, Kato S, Hirate M, et al. A potent neutralizing monoclonal antibody to human growth hormone suppresses insulin-like growth factor-1 in female rats. Endocrinology. 2024;165(5):bqae033. https:\/\/doi.org\/10.1210\/endocr\/bqae033.","DOI":"10.1210\/endocr\/bqae033"},{"issue":"3","key":"2312_CR86","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/ejendo\/lvaf043","volume":"192","author":"G Ravel","year":"2025","unstructured":"Ravel G, Gaume X, Berardet C, Chalmey C, Kurasaki H, Tomiyama T, et al. Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo. Eur J Endocrinol. 2025;192(3):299\u2013307.","journal-title":"Eur J Endocrinol"},{"key":"2312_CR87","doi-asserted-by":"crossref","unstructured":"Allas S, Ravel G, Farrell C, Fillon S, Taha O, Culler MD, et al. A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813, a novel small peptide growth hormone receptor antagonist, in healthy subjects. J Endocr Soc. 2024;8(Supplement 1):bvae163.1100.","DOI":"10.1210\/jendso\/bvae163.1100"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02312-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:03:57Z","timestamp":1778861037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02312-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2312"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02312-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NAT has no conflicts of interest to disclose. BMKB has been the PI of grant support to Mass General Hospital from Alexion, Crinetics and DebioPharm; and has received occasional consulting honoraria from Alexion, Camurus, Crinetics, and Recordati.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Participation"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Both authors (NAT and BMKB) contributed to this manuscript, including writing and editing the original draft and revised version. Both authors read and approved the final version of the manuscript\u00a0and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}